Results 211 to 220 of about 765,049 (358)
Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study [PDF]
Tobias Veit +15 more
openalex +1 more source
In this review, the pathological, molecular, and cellular changes observed in the COVID‐19 lung are compared to those in the laboratory rat treated with monocrotaline (MCT). Similarities that reflect common changes associated with inflammation and endothelial cell dysfunction are observed in both states, leading to a lung pathology characterized by ...
Luke P. Kris +3 more
wiley +1 more source
Multi‐omics analysis revealed that FOS supplementation increased the abundance of Phascolarctobacterium, GCA‐900066575, Shuttleworthia, Olsenella, Eubacterium_hallii_group while decreasing Alistipes. It also influenced the metabolism of S‐lactoylglutathione, p‐cresol glucuronate, 2‐phenylethanol glucuronide, propionic acid, dulcitol, and inhibited the ...
Dan Song +11 more
wiley +1 more source
Interstitial Lung Disease in 2025-Progress, Challenges, and Hope Ahead. [PDF]
Sehgal S, Mehta A.
europepmc +1 more source
Incidence and prevalence of systemic sclerosis and systemic sclerosis with interstitial lung disease in the United States [PDF]
Yanni Fan +3 more
openalex +1 more source
Mucosal‐Associated Invariant T Cells in Rheumatic Diseases
Mucosal‐associated invariant T (MAIT) cells are innate‐like T cells defined by their semi‐invariant T cell receptor and restriction by the major histocompatibility complex class I–related molecule (MR1). These cells are primarily activated by microbial‐derived metabolites presented by MR1 or by cytokines.
Manon Lesturgie‐Talarek +7 more
wiley +1 more source
Objective We used data from the placebo arm of the Safety and Efficacy of Nintedanib in Systemic Sclerosis (SENSCIS) trial to determine the prognostic/predictive significance of peripheral blood cell (PBC) transcript modules for the course of forced vital capacity (FVC) in patients with systemic sclerosis–associated interstitial lung disease (SSc‐ILD ...
Shervin Assassi +6 more
wiley +1 more source
Antisynthetase syndrome presenting as interstitial lung disease: a case report [PDF]
Aliena Badshah +3 more
openalex +1 more source
Objective To evaluate the applicability of the 2016 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR)/Paediatric Rheumatology International Trials Organisation (PRINTO) macrophage activation syndrome (MAS) classification criteria in patients with Still disease and systemic juvenile idiopathic arthritis ...
Remco G. A. Erkens +14 more
wiley +1 more source

